GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Inventories, Raw Materials & Components

Scandion Oncology AS (OSTO:SCOL) Inventories, Raw Materials & Components : kr0.00 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Inventories, Raw Materials & Components?

Scandion Oncology AS's inventories, raw materials & components for the quarter that ended in Sep. 2024 was kr0.00 Mil.


Scandion Oncology AS Inventories, Raw Materials & Components Historical Data

The historical data trend for Scandion Oncology AS's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Inventories, Raw Materials & Components Chart

Scandion Oncology AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Scandion Oncology AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Scandion Oncology AS Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Scandion Oncology AS Business Description

Industry
Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology AS Headlines

No Headlines